Lipid Composition for FAS-201 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 1.485 | 1.20 | 99 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
Total | 1.500 µmol/vial | 1.21 mg/vial | 100 |
Lipid Composition for FAS-202 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 1.350 | 1.09 | 90 |
L-alpha-phosphatidylcholine | 0.135 | 0.10 | 9 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
Total | 1.500 µmol/vial | 1.20 mg/vial | 100 |
Lipid Composition for FAS-203 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 1.200 | 0.97 | 80 |
L-alpha-phosphatidylcholine | 0.285 | 0.22 | 19 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
Total | 1.500 µmol/vial | 1.20 mg/vial | 100 |
Lipid Composition for FAS-204 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 1.050 | 0.85 | 70 |
L-alpha-phosphatidylcholine | 0.435 | 0.34 | 29 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
Total | 1.500 µmol/vial | 1.20 mg/vial | 100 |
Lipid Composition for FAS-205 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 0.900 | 0.73 | 60 |
L-alpha-phosphatidylcholine | 0.585 | 0.45 | 39 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
Total | 1.500 µmol/vial | 1.19 mg/vial | 100 |
Lipid Composition for FAS-206 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 0.750 | 0.60 | 50 |
L-alpha-phosphatidylcholine | 0.735 | 0.57 | 49 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
Total | 1.500 µmol/vial | 1.18 mg/vial | 100 |
Lipid Composition for FAS-207 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 0.600 | 0.48 | 40 |
L-alpha-phosphatidylcholine | 0.885 | 0.68 | 59 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
Total | 1.500 µmol/vial | 1.17 mg/vial | 100 |
Lipid Composition for FAS-208 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 0.450 | 0.36 | 30 |
L-alpha-phosphatidylcholine | 1.035 | 0.80 | 69 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
Total | 1.500 µmol/vial | 1.17 mg/vial | 100 |
Lipid Composition for FAS-209 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 0.300 | 0.24 | 20 |
L-alpha-phosphatidylcholine | 1.185 | 0.91 | 79 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
Total | 1.500 µmol/vial | 1.16 mg/vial | 100 |
Lipid Composition for FAS-210 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 0.150 | 0.12 | 10 |
L-alpha-phosphatidylcholine | 1.335 | 1.03 | 89 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
Total | 1.500 µmol/vial | 1.16 mg/vial | 100 |
Lipid Composition for FAS-211 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 1.485 | 1.20 | 99 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.01 | 1 |
Total | 1.500 µmol/vial | 1.21 mg/vial | 100 |
Lipid Composition for FAS-212 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 1.350 | 1.09 | 90 |
L-alpha-phosphatidylcholine | 0.135 | 0.10 | 9 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
Total | 1.500 µmol/vial | 1.21 mg/vial | 100 |
Lipid Composition for FAS-213 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 1.200 | 0.97 | 80 |
L-alpha-phosphatidylcholine | 0.285 | 0.22 | 19 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
Total | 1.500 µmol/vial | 1.21 mg/vial | 100 |
Lipid Composition for FAS-214 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 1.050 | 0.85 | 70 |
L-alpha-phosphatidylcholine | 0.435 | 0.34 | 29 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
Total | 1.500 µmol/vial | 1.21 mg/vial | 100 |
Lipid Composition for FAS-215 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 0.900 | 0.73 | 60 |
L-alpha-phosphatidylcholine | 0.585 | 0.45 | 39 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
Total | 1.500 µmol/vial | 1.20 mg/vial | 100 |
Lipid Composition for FAS-216 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 0.750 | 0.60 | 50 |
L-alpha-phosphatidylcholine | 0.735 | 0.57 | 49 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
Total | 1.500 µmol/vial | 1.19 mg/vial | 100 |
Lipid Composition for FAS-217 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 0.600 | 0.48 | 40 |
L-alpha-phosphatidylcholine | 0.885 | 0.68 | 59 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
Total | 1.500 µmol/vial | 1.18 mg/vial | 100 |
Lipid Composition for FAS-218 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 0.450 | 0.36 | 30 |
L-alpha-phosphatidylcholine | 1.035 | 0.80 | 69 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
Total | 1.500 µmol/vial | 1.18 mg/vial | 100 |
Lipid Composition for FAS-219 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 0.300 | 0.24 | 20 |
L-alpha-phosphatidylcholine | 1.185 | 0.91 | 79 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
Total | 1.500 µmol/vial | 1.17 mg/vial | 100 |
Lipid Composition for FAS-220 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
---|---|---|---|
L-alpha-phosphatidylserine | 0.150 | 0.12 | 10 |
L-alpha-phosphatidylcholine | 1.335 | 1.03 | 89 |
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
Total | 1.500 µmol/vial | 1.17 mg/vial | 100 |